{"createdAt":"8/2/2020, 2:53:08 PM","timestamp":1596394388723,"Company ID number":"900","DMX_ISSUER_NAME":"Meihua Holdings Group Co., Ltd","DMX_ISSUER_ID":"IID000000002135000","Country of Classification":"CHINA","name":"MeiHua Holdings Group Co Ltd ","code":"600873","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"梅花生物科技集团股份有限公司_王爱军","group":"board","name":"王爱军","title":"董事长,董事","isMale":false,"age":"48","degree":"","salary":"201.0万","stockAmount":"7132万","description":"王爱军女士,1972年出生,中国国籍,汉族,曾分别在北京国际商务学院、北京大学高层管理研修班进修会计学、管理学,曾任原梅花集团董事、总经理,现任上市公司董事长。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_何君","group":"board","name":"何君","title":"董事","isMale":true,"age":"46","degree":"大专","salary":"360.0万","stockAmount":"2345万","description":"何君先生,1974年出生,中国国籍,中共党员,汉族,曾在胜芳建设分局工作,2000年加入梅花味精,曾任原梅花集团董事、副总经理。现任上市公司董事、副总经理。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_梁宇博","group":"board","name":"梁宇博","title":"董事","isMale":true,"age":"56","degree":"","salary":"418.0万","stockAmount":"5451万","description":"梁宇博先生,1964年出生,中国国籍,汉族。梁宇博先生2000年加入梅花味精,曾任原梅花集团董事、副总经理,现任上市公司董事、副总经理。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_郭春明","group":"board","name":"郭春明","title":"独立董事","isMale":true,"age":"45","degree":"博士","salary":"20.00万","stockAmount":"-","description":"郭春明先生,1975年生,中国国籍,汉族,中共党员,会计学副教授,管理学博士,北京大学光华管理学院EMBA,1996年-2005年为太原理工大学会计学讲师,2005年7月至2008年8月为南京财经大学会计学院会计系会计学副教授、硕士生导师,2008年8月至2016年6月在万华化学集团股份有限公司任审计部总经理、宁波万华财务总监等职,2016年6月至今为无锡北大博雅控股集团有限公司副总裁。郭春明先生曾在国内一级期刊发表论文5篇,2篇被EI全文索引,核心期刊发表论文十三篇,主持国家博士后基金两项,研究方向分别为财务管理、内部控制等,曾参与国家自然基金、国家软科学研究项目多项,并曾获得过“宁波市先进会计工作者”荣誉称号。郭春明先生已获得上海证券交易所颁发的独立董事资格证书,现任梅花生物科技集团股份有限公司独立董事。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_罗青华","group":"board","name":"罗青华","title":"独立董事","isMale":true,"age":"48","degree":"本科","salary":"20.00万","stockAmount":"-","description":"罗青华先生,中国国籍,1972年8月出生,本科学历。1990年7月至1996年6月,任中美史克制药有限公司人力资源部职员;1996年7月至1997年10月,任罗纳普朗克(中国)公司人力资源总监助理;1997年11月至1998年12月,任壳牌(中国)公司投资企业人力资源经理;1999年1月至今任佐佑管理顾问公司董事长。已取得中国证监会认可的独立董事资格证书。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_常利斌","group":"supervisoryCommittee","name":"常利斌","title":"监事会主席","isMale":true,"age":"51","degree":"","salary":"292.0万","stockAmount":"-","description":"常利斌先生,1969年生,中国国籍,汉族,2005年2月加入原梅花集团,曾任上市公司通辽基地工程负责人、新疆项目技术部负责人、工程公司负责人等职,现为公司技术总工、医药氨基酸事业部部长、公司监事会主席。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_崔丽芝","group":"supervisoryCommittee","name":"崔丽芝","title":"监事","isMale":false,"age":"50","degree":"大专","salary":"51.00万","stockAmount":"-","description":"崔丽芝女士,1970年生,中国国籍,汉族,中共党员,2002年加入梅花味精,曾任营销公司内勤经理、食品原料部部长等职,2008年10月开始在江南大学在职进修管理课程,现为营销公司物流运营部营运二处处长。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_杨雪梅","group":"supervisoryCommittee","name":"杨雪梅","title":"职工监事","isMale":false,"age":"45","degree":"","salary":"50.00万","stockAmount":"-","description":"杨雪梅女士,1975年出生,籍贯河北省唐山市,2001年至今历任梅花生物科技集团股份有限公司营销中心调度、生产计划部主管、计财部部长等职,现为梅花生物科技集团股份有限公司肥料事业部兼多糖事业部副部长,公司职工监事。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_何君","group":"manager","name":"何君","title":"总经理","isMale":true,"age":"46","degree":"大专","salary":"360.0万","stockAmount":"2345万","description":"何君先生,1974年出生,中国国籍,中共党员,汉族,曾在胜芳建设分局工作,2000年加入梅花味精,曾任原梅花集团董事、副总经理。现任上市公司董事、副总经理。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_刘现芳","group":"manager","name":"刘现芳","title":"董事会秘书","isMale":false,"age":"36","degree":"本科","salary":"37.00万","stockAmount":"22.5万","description":"刘现芳女士,1984年生,中国国籍,本科学历,2006年7月加入公司,历任上市公司证券部信息披露专员、信息披露主管、上市公司证券事务代表、董事会秘书等职位,现任上市公司董事会秘书。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_梁宇博","group":"manager","name":"梁宇博","title":"副总经理","isMale":true,"age":"56","degree":"","salary":"418.0万","stockAmount":"5451万","description":"梁宇博先生,1964年出生,中国国籍,汉族。梁宇博先生2000年加入梅花味精,曾任原梅花集团董事、副总经理,现任上市公司董事、副总经理。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_王有","group":"manager","name":"王有","title":"副总经理","isMale":true,"age":"45","degree":"本科","salary":"243.0万","stockAmount":"49.98万","description":"王有先生,1975年生,中国国籍,本科学历,中共党员,2002年7月加入公司,历任通辽梅花生产办经理、氨基酸项目部经理、通辽东区生产经理、通辽梅花副总经理,现为子公司新疆梅花总经理、上市公司副总经理。","lastUpdated":"2019-12-28"},{"id":"梅花生物科技集团股份有限公司_王丽红","group":"manager","name":"王丽红","title":"财务总监","isMale":false,"age":"39","degree":"","salary":"21.00万","stockAmount":"6.24万","description":"王丽红女士,1981年生,中国国籍,中共党员,天津商业大学会计学专业毕业,注册会计师。2005年起先后在梅花集团财务部担任会计、会计主管、会计处经理、总账会计等职务。在财务核算、财务分析以及财务管理等方面有丰富的经验及专业知识。现任上市公司财务总监。","lastUpdated":"2019-12-28"}],"companyName":"梅花生物科技集团股份有限公司","province":"西藏自治区","englishName":"Meihua Holdings Group Co Ltd","industry":"农林牧渔 — 农产品加工","website":"www.meihuagrp.com","mainBusiness":"氨基酸系列产品、味精、谷氨酸等产品的生产和销售","productsName":["谷氨酸","谷氨酸钠","呈味核苷酸二钠","肌苷酸二钠","食品级黄原胶","海藻糖","纳他霉素","赖氨酸","苏氨酸","色氨酸","饲料级缬氨酸","味精渣，淀粉附产品饲料纤维","玉米胚芽","菌体蛋白","谷氨酰胺","脯氨酸","亮氨酸","异亮氨酸","医药级缬氨酸","肌苷","鸟苷","腺苷","普鲁兰多糖","石油级黄原胶","药用胶囊","生物有机肥"],"actualController":"孟庆山、王爱军、何君","actualControllerSharePercentage":"27.51、2.30、0.76%","registeredCapital":"31亿元","employeeAmount":"11671","phone":"86-0316-2359652","location":"河北省廊坊市广阳区经济技术开发区华祥路66号","chineseDescription":"梅花生物科技集团股份有限公司的主营业务为氨基酸系列产品、味精、谷氨酸等产品的生产和销售；公司的主要产品有食品味觉性状优化产品、动物营养氨基酸类产品、人类医用氨基酸类；公司的产品主要销售给国内外知名的食品、酱料、 调味品、饲料、医药原料药等加工企业。公司的研发技术水平、技术能力及规范管理得到了国家级、省级及同行业的高度认可，先后获得了国家高新技术企业、全国氨基酸行业分析测试中心、CNAS认可实验室。","foundedDate":"1995-02-09","goPublicDate":"1995-02-17","companyHistory":"(一)公司注册地、组织形式和总部地址\n　　梅花生物科技集团股份有限公司（以下简称“公司”或“本公司”）前身为五洲明珠股份有限公司（以下简称“五洲明珠”），并于1995年2月17日在上海证券交易所上市，后吸收合并原梅花生物科技集团股份有限公司（以下简称“原梅花集团”）名称由“五洲明珠股份有限公司”更名为“梅花生物科技集团股份有限公司”，于2011年3月3日完成工商变更登记。现企业统一信用代码号为91540000219667563J。\n　　经过历年的派送红股、配售新股、转增股本及增发新股，截止2016年12月31日，本公司累计股本总数3,108,226,603股，注册资本为3,108,226,603.00元，注册地址：拉萨市金珠西路189号，实际控制人为：孟庆山。\n　　原梅花集团原名河北梅花味精集团有限公司，是由自然人孟庆山、杨维永、胡继军出资组建，并于2002年4月23日取得河北省工商行政管理局核发的131081000002308号《企业法人营业执照》。\n　　五洲明珠是以成都西藏饭店、西藏自治区信托投资公司、西藏兴藏实业开发公司为发起人，于1995年1月6日向社会公众公开发行股票3,000万股，以募集方式设立的股份有限公司。1995年2月9日，五洲明珠在西藏自治区拉萨市注册登记，企业法人营业执照号为5400001000327，股本总额为7,300万股。同年2月17日经中国证监会批准本公司社会公众股在上海证券交易所上市流通，股票代码为600873。\n　　1995年8月12日，本公司股东大会审议通过的《股利分配方案》，于1995年8月21日实施了向全体股东每10股送3股股票的1994年度分配方案。此次分配以7,300万股为基数，共分配2,190万股，分配后本公司股本总数达到9,490万股。\n　　1996年12月19日，本公司召开1996年临时股东大会审议通过《配股方案》，于1997年8月12日实施了向全体股东每10股配3股股票的配股方案。此次配股以9,490万股为基数，共配售13,336,603股（其中包括转配股1,436,603股），配股完成后本公司股本总数达到108,236,603股。\n　　2003年2月16日，山东五洲投资集团有限公司及潍坊渤海实业有限公司分别与西藏自治区国有资产经营公司（其所持股份由西藏自治区国有资产管理局无偿划转所得）签订国有股权转让协议，山东五洲投资集团有限公司受让西藏自治区国有资产经营公司所持有的本公司国有法人股27,102,445股，占本公司总股本的25.04%，成为本公司第一大股东；潍坊渤海实业有限公司受让21,535,555股，占本公司总股本的19.90%。以上股权转让于2003年5月29日经国务院国有资产监督管理委员会“国资产权函【2003】25号”文件正式批准。2003年8月11日，本公司与山东五洲投资集团有限公司、山东五洲电气股份有限公司签署《资产置换协议》，实施重大资产置换，该次置换完成后，股本总额未发生变化。\n　　2006年5月22日，本公司召开“股权分置改革相关股东会议”，审议通过了公司股权分置改革方案，公司全体非流通股东向全体流通股东每10股送2.8股。公司于2006年6月2日完成了上述股权分置改革方案的实施。\n　　2016年年度报告2010年12月22日经中国证券监督管理委员会证监许可[2010]1888号《关于核准五洲明珠股份有限公司重大资产出售及以新增股份吸收合并梅花生物科技集团股份有限公司的批复》文核准，本公司向原梅花集团发行900,000,000股人民币普通股用于购买其所有股东享有的全部股东权益。\n　　2010年12月24日，立信大华会计师事务所有限公司为本次股本变更出具了立信大华验字[2010]200号《验资报告》。2010年12月31日，本公司取得了《中国证券登记结算有限责任公司上海分公司证券变更登记证明》，本公司证券登记股本为1,008,236,603股。\n　　2011年3月28日，公司2010年年度股东大会审议通过实施资本公积转增股本方案，以1,008,236,603股为基础，每10股转增16.861股，转增完成后公司总股本为2,708,236,603股。2011年4月12日，本公司在中国证券登记结算有限责任公司上海分公司完成股份变动登记，本公司证券登记股本为2,708,236,603股。\n　　根据本公司2011年4月22日第六届董事会第五次会议决议、2012年2月22日第六届董事会第十四次会议决议、2012年3月22日召开的2011年年度股东大会决议和修改后章程的规定，并经中国证券监督管理委员会证监许可字[2012]1262号文《关于核准梅花生物科技集团股份有限公司非公开发行股票的批复》的核准，同意公司非公开发行不超过人民币普通股（A股）4亿股。\n　　本公司于2013年3月26日向特定对象非公开发行人民币普通股(A股)399,990,000股，本次发行完成后公司总股本为3,108,226,603股。2013年3月29日，本公司在中国证券登记结算有限责任公司上海分公司办理登记托管手续。\n　　根据本公司2018年5月30日第八届董事会第十五次会议决议、2018年6月20日第八届董事会第十七次会议决议、2018年6月20日2017年年度股东大会决议，本公司将34,534,865股库存股以2.46元/股价格作为股权激励计划，授予在梅花生物公司任职的董事、高级管理人员、核心管理人员、业务技术骨干，激励对象总人数为109人，注册资本不变。\n　　根据本公司2018年12月7日第八届董事会第二十二次会议决议、2018年第一次临时股东大会决议，本公司对放弃认购51,565股股票作注销处理，注销完成后，公司总股本为3,108,175,038股。\n　　根据本公司2019年6月第八届董事会第二十八次会议决议、2019年6月24日2018年年度股东大会决议，本公司因激励对象离职和未完成个人绩效考核而回购388.54万股限制性股票进行注销，注销完成后，公司总股本为3,104,289,638股。收起▲","shareholders":[{"organizationId":"","holderName":"孟庆山","totalShare":"8.54亿","sharePercentage":"27.51%"},{"organizationId":"","holderName":"胡继军","totalShare":"1.86亿","sharePercentage":"6.00%"},{"organizationId":"T000073058","holderName":"中国证券金融股份有限公司","totalShare":"1.51亿","sharePercentage":"4.88%"},{"organizationId":"","holderName":"杨维永","totalShare":"7881.05万","sharePercentage":"2.54%"},{"organizationId":"","holderName":"王爱军","totalShare":"7131.63万","sharePercentage":"2.30%"},{"organizationId":"","holderName":"北京隆慧投资有限公司-隆慧汇晨战略投资私募证券投资基金","totalShare":"5895.84万","sharePercentage":"1.90%"},{"organizationId":"","holderName":"梁宇博","totalShare":"5486.85万","sharePercentage":"1.77%"},{"organizationId":"","holderName":"梅花生物科技集团股份有限公司回购专用证券账户","totalShare":"3328.46万","sharePercentage":"1.07%"},{"organizationId":"","holderName":"梅花生物科技集团股份有限公司-2017年第一期员工持股计划","totalShare":"2884.59万","sharePercentage":"0.93%"},{"organizationId":"","holderName":"何君","totalShare":"2344.98万","sharePercentage":"0.76%"}],"englishDescription":"MeiHua Holdings Group Co., Ltd is a China-based company, principally engaged in the production and distribution of biological fermented products. The Company principally provides animal nutritional amino acids, human medical amino acids and food taste optimization products. The Company distributes its products in domestic markets and to overseas markets.","englishIndustry":"Chemical Manufacturing","Price to earnings (ttm)":"20.67","Price to sales (ttm)":"1.21","Price to book (mrq)":"2.01","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"72.23","Lt debt to equity (mrq)":"44.69","Return on investment (ttm)":"7.26","Return on equity (ttm)":"4.80","Income statement":{},"Balance sheet":{},"Cash flow":{"Cash receipts":"15,073.74","Cash payments":"(9,669.78)","Cash taxes paid":"(547.79)","Changes in working capital":"(2,058.22)","Cash from operating activities":"2,797.94","Capital expenditures":"(1,142.43)","Other investing cash flow items, total":"292.32","Cash from investing activities":"(850.12)","Financing cash flow items":"75.90","Total cash dividends paid":"(1,253.10)","Issuance (retirement) of debt, net":"(190.24)","Cash from financing activities":"(1,367.44)","Foreign exchange effects":"26.69","Net change in cash":"607.07"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"5.94","52 Week High":"6.09","52 Week Low":"3.86","Pricing date":"","10 Day Average Trading Volume":"70.71","Market Capitalization":"18,414.13","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"814.46","Beta":"1.08","1 Day Price Change":"7.22","13 Week Price Return (Daily)":"30.26","26 Week Price Return (Daily)":"38.46","5 Day Price Return (Daily)":"14.45","52 Week Price Return (Daily)":"23.75","Year To Date Price Return (Daily)":"33.48","Month to Date Price Return (Daily)":"30.84","Price Relative to S&P500 (4 Week)":"20.90","Price Relative to S&P500 (13 Week)":"12.56","Price Relative to S&P500 (26 Week)":"24.51","Price Relative to S&P500 (52 Week)":"8.75","Price Relative to S&P500 (YTD)":"23.00"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.32","EPS excl. Extra Items (TTM)":"0.29","EPS Normalized (Annual)":"0.33","Revenue per Share (Annual)":"4.69","Revenue per Share (TTM)":"4.89","Book Value (Per Share Annual)":"2.89","Book Value (Per Share Quarterly)":"2.95","Tangible Book Value (Per Share Annual)":"2.46","Tangible Book Value (Per Share Quarterly)":"2.53","Cash Per Share (Per Share Annual)":"0.72","Cash Per Share (Per Share Quarterly)":"0.63","Cash Flow (Per Share Annual)":"0.76","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.26","Dividends (Per Share TTM)":"0.26","EBITD (Per Share TTM)":"0.42","EPS Basic excl. Extra Items (Annual)":"0.32","EPS Basic excl. Extra Items (TTM)":"0.29","EPS incl. Extra Items (Annual)":"0.32","EPS incl. Extra Items (TTM)":"0.29","Free Cash Flow (Per Share TTM)":"0.12","Dividend (Per Share 5Y)":"0.26"},"Valuation":{"P/E excl. Extra Items (Annual)":"18.65","P/E excl. Extra Items (TTM)":"20.67","P/E Normalized (Annual)":"18.06","Price to sales (Annual)":"1.27","Price to sales (TTM)":"1.21","Price to Tangible Book (Annual)":"2.41","Price to Tangible Book (Quarterly)":"2.35","Price to Free Cash Flow (Per Share Annual)":"45.76","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"47.59","Price to Book (Annual)":"2.05","Price to Book (Quarterly)":"2.01","P/E Basic excl. Extra Items (TTM)":"15.35","P/E excl. Extra Items High (TTM)":"66.14","P/E excl. Extra Items Low (TTM)":"10.24","P/E incl. Extra Items (TTM)":"20.67","Net Debt (Interim)":"4,660.33","Net Debt (Annual)":"4,419.71","Dividend Yield (5Y)":"4.48","Dividend Yield":"4.38","Current Dividend Yield (TTM)":"4.38"},"Financial Strength":{"Free Cash Flow (Annual)":"402.41","Current Ratio (Annual)":"0.99","Net Interest coverage (Annual)":"6.60","Long Term Debt/Equity (Annual)":"45.31","Payout Ratio (Annual)":"81.64","Quick Ratio (Annual)":"0.60","Total Debt/Total Equity (Annual)":"74.20","Current EV/Free Cash Flow (Annual)":"--","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.08","Long Term Debt/Equity (Quarterly)":"44.69","Quick Ratio (Quarterly)":"0.67","Total Debt/Total Equity (Quarterly)":"72.23","Free Cash Flow (TTM)":"386.96","Net Interest Coverage (TTM)":"5.35","Payout Ratio (TTM)":"90.44"},"Margins":{"Gross Margin (Annual)":"22.20","Gross Margin (TTM)":"20.59","Net Profit Margin % (Annual)":"6.90","Net Profit Margin (TTM)":"5.96","Operating Margin (Annual)":"8.07","Operating Margin (TTM)":"7.01","Pretax Margin (TTM)":"6.99","Pretax Margin (Annual)":"8.02","Operating Margin (5Y)":"8.65","Pretax Margin (5Y)":"9.04","Free Operating Cash Flow/Revenue (5Y)":"6.29","Free Operating Cash Flow/Revenue (TTM)":"2.55","Gross Margin (5Y)":"23.48","Net Profit Margin (5Y)":"7.72"},"Management Effectiveness":{"Return on Assets (Annual)":"5.23","Return on Equity (TTM)":"4.80","Return on Average Equity (Annual)":"10.93","Return on Average equity (TTM)":"9.59","Return on Investment (Annual)":"8.22","Return on Investment (TTM)":"7.26","Return on Average Assets (5Y)":"5.18","Return on Average Equity (5Y)":"10.47","Return on Investment (5Y)":"8.10","Asset Turnover (Annual)":"0.76","Asset Turnover (TTM)":"0.80","Inventory Turnover (Annual)":"5.66","Inventory Turnover (TTM)":"6.52","Net Income/Employee (Annual)":"88,594.79","Net Income/Employee (TTM)":"77,617.36","Receivables Turnover (Annual)":"36.41","Receivables Turnover (TTM)":"28.33","Revenue/Employee (Annual)":"1,284,798.00","Revenue/Employee (TTM)":"1,301,496.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"19.06","Revenue Growth Rate (5Y)":"8.09","EPS Growth (Quarterly YoY)":"-28.06","EPS Growth (TTM YoY)":"-18.46","EPS Growth Rate (5Y)":"14.62","Dividend Growth Rate (3Y)":"-4.66","Revenue Growth (TTM YoY)":"18.86","Revenue Growth (Per Share 5Y)":"8.11","Revenue Growth Rate (3Y)":"9.47","EPS Growth Rate (3Y)":"-1.69","Book Value Growth Rate (Per Share 5Y)":"1.82","Tangible Book Value Total Equity CAGR (5Y)":"2.01","Capital Spending growth rate 5 year":"17.43","EBITDA CAGR (5Y)":"7.56","EBITDA Interim CAGR (5Y)":"4.18","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"-7.45","Net Profit Margin Growth Rate (5Y)":"6.08"},"Income Statement":{"Revenue (Annual)":"14,553.55","Revenue (TTM)":"15,189.76","EBITD (Annual)":"2,789.62","EBITD (TTM)":"1,310.42","Earnings Before Taxes (Annual)":"1,167.58","Earnings Before Taxes (TTM)":"1,061.29","Net Income to Common (Annual)":"988.64","Net Income to Common (TTM)":"892.47","Earnings Before Taxes Normalized (Annual)":"1,205.21","Net Income Available to Common Normalized (Annual)":"1,020.99","Diluted Normalized EPS excl. Extra Items (TTM)":"0.29"}}}